China Biologic Products Holdings Financial Statements (CBPO)
|
|
|
|
Report date
|
|
|
23.02.2017 |
28.02.2018 |
06.03.2019 |
12.03.2020 |
31.12.2020 |
|
31.12.2020 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
341.2 |
370.4 |
466.9 |
503.7 |
524.4 |
|
524.4 |
|
Operating Income, bln rub |
|
|
143.9 |
135.9 |
146.2 |
163.6 |
195.4 |
|
195.4 |
|
EBITDA, bln rub |
? |
|
142.9 |
145.6 |
169.7 |
193.7 |
215.5 |
|
215.5 |
|
Net profit, bln rub |
? |
|
104.8 |
67.9 |
128.1 |
138.8 |
152.3 |
|
152.3 |
|
|
OCF, bln rub |
? |
|
123.3 |
102.2 |
103.9 |
229.3 |
258.5 |
|
258.5 |
|
CAPEX, bln rub |
? |
|
51.0 |
38.3 |
36.7 |
24.4 |
21.0 |
|
21.0 |
|
FCF, bln rub |
? |
|
72.3 |
63.9 |
67.2 |
204.9 |
237.4 |
|
237.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
73.2 |
109.0 |
173.9 |
165.4 |
149.1 |
|
149.1 |
|
Cost of production, bln rub |
|
|
124.0 |
125.5 |
146.8 |
174.7 |
179.9 |
|
179.9 |
|
R&D, bln rub |
|
|
7.02 |
6.50 |
9.52 |
11.7 |
8.58 |
|
8.58 |
|
Interest expenses, bln rub |
|
|
0.254 |
0.583 |
0.338 |
0.558 |
0.324 |
|
0.324 |
|
|
Assets, bln rub |
|
|
605.0 |
809.1 |
2 010 |
1 938 |
2 260 |
|
2 260 |
|
Net Assets, bln rub |
? |
|
521.1 |
664.3 |
1 845 |
1 775 |
2 082 |
|
2 082 |
|
Debt, bln rub |
|
|
0.000 |
0.000 |
0.000 |
1.17 |
0.000 |
|
0.000 |
|
Cash, bln rub |
|
|
183.8 |
242.2 |
952.4 |
927.3 |
1 193 |
|
1 193 |
|
Net debt, bln rub |
|
|
-183.8 |
-242.2 |
-952.4 |
-926.1 |
-1 193 |
|
-1 193 |
|
|
Ordinary share price, rub |
|
|
107.5 |
78.8 |
75.9 |
116.4 |
118.1 |
|
117.9 |
|
Number of ordinary shares, mln |
|
|
26.8 |
27.4 |
35.4 |
38.9 |
38.7 |
|
38.7 |
|
|
Market cap, bln rub |
|
|
2 887 |
2 155 |
2 690 |
4 527 |
4 566 |
|
4 562 |
|
EV, bln rub |
? |
|
2 703 |
1 913 |
1 737 |
3 601 |
3 373 |
|
3 369 |
|
Book value, bln rub |
|
|
498 |
639 |
1 446 |
1 394 |
1 682 |
|
1 682 |
|
|
EPS, rub |
? |
|
3.90 |
2.48 |
3.61 |
3.57 |
3.94 |
|
3.94 |
|
FCF/share, rub |
|
|
2.69 |
2.34 |
1.90 |
5.27 |
6.14 |
|
6.14 |
|
BV/share, rub |
|
|
18.5 |
23.4 |
40.8 |
35.8 |
43.5 |
|
43.5 |
|
|
EBITDA margin, % |
? |
|
41.9% |
39.3% |
36.3% |
38.5% |
41.1% |
|
41.1% |
|
Net margin, % |
? |
|
30.7% |
18.3% |
27.4% |
27.6% |
29.0% |
|
29.0% |
|
FCF yield, % |
? |
|
2.50% |
2.96% |
2.50% |
4.53% |
5.20% |
|
5.21% |
|
ROE, % |
? |
|
20.1% |
10.2% |
6.94% |
7.82% |
7.32% |
|
7.32% |
|
ROA, % |
? |
|
17.3% |
8.40% |
6.37% |
7.16% |
6.74% |
|
6.74% |
|
|
P/E |
? |
|
27.6 |
31.7 |
21.0 |
32.6 |
30.0 |
|
30.0 |
|
P/FCF |
|
|
40.0 |
33.7 |
40.0 |
22.1 |
19.2 |
|
19.2 |
|
P/S |
? |
|
8.46 |
5.82 |
5.76 |
8.99 |
8.71 |
|
8.70 |
|
P/BV |
? |
|
5.80 |
3.37 |
1.86 |
3.25 |
2.71 |
|
2.71 |
|
EV/EBITDA |
? |
|
18.9 |
13.1 |
10.2 |
18.6 |
15.6 |
|
15.6 |
|
Debt/EBITDA |
|
|
-1.29 |
-1.66 |
-5.61 |
-4.78 |
-5.54 |
|
-5.54 |
|
|
R&D/CAPEX, % |
|
|
13.8% |
17.0% |
25.9% |
48.0% |
40.8% |
|
40.8% |
|
|
CAPEX/Revenue, % |
|
|
15.0% |
10.3% |
7.86% |
4.85% |
4.01% |
|
4.01% |
|
| China Biologic Products Holdings shareholders |
